^
Association details:
| Biomarker: | SRSF2 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
VENETOCLAX AND HYPOMETHYLATING AGENT COMBINATIONS FOR THE TREATMENT OF ADVANCED MYELOPROLIFERATIVE NEOPLASMS AND ACUTE MYELOID LEUKEMIA WITH EXTRAMEDULLARY DISEASE
Published date:
05/12/2022
Excerpt:
Patients with a mutation in the SRSF2 gene had a higher composite CR rate (80% versus 20%; p= 0.0082)...While limited by a small sample size, our study suggests that HMA/venetoclax may be associated with more favorable outcomes in patients with advanced MDS/MPN compared to those with advanced MPN. Mutations in the SRSF2 gene may also be associated with more favorable outcomes.
